Cancer research is an essential part of national cancer control programmes, and the emerging economies of Central and Eastern Europe (CEE) and the Russian Federation and Central Asia (R-CA) (Commonwealth of Independent States) remain relatively understudied. Here, we map the cancer research activity from the 29 countries across these regions over a 10-year period (2007-2016), using a standard scientometric approach. Research activity was compared with the countries' wealth and with the disease burden from different cancers, and analyses were also performed by the research domain (e.g. fundamental cancer biology, surgery). We found that although there was a correlation between outputs and national wealth, there were many outliers; the CEE countries publishing relatively more, and the R-CA, less. Outputs reflected cancer burdens, but there was a relative paucity of research on lung, colorectal, gastric and pancreatic cancer, as well as research domains such as screening and palliative care. Clinical trials accounted for only 3% of all research outputs from all countries, and were very international, with on average 1.5 CEE countries and 8.0 others involved in each article, and they were heavily cited (on average, 84 times in 5 years). Poland was by far the most research-active country, but significant needs and opportunities have been identified to expand the cancer research activity in all CEE and R-CA countries to enhance national cancer control planning.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejca.2018.08.024 | DOI Listing |
JMIR Res Protoc
January 2025
National Radiotherapy, Oncology and Nuclear Medicine Centre, Korle-bu Teaching Hospital, Accra, Ghana.
Background: Cancer is a leading cause of global mortality, accounting for nearly 10 million deaths in 2020. This is projected to increase by more than 60% by 2040, particularly in low- and middle-income countries. Yet, palliative and psychosocial oncology care is very limited in these countries.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
College of Public Health, The Ohio State University, Columbus, OH, United States.
Background: Young gay, bisexual, and other men who have sex with men have been referred to as a "hard-to-reach" or "hidden" community in terms of recruiting for research studies. With widespread internet use among this group and young adults in general, web-based avenues represent an important approach for reaching and recruiting members of this community. However, little is known about how participants recruited from various web-based sources may differ from one another.
View Article and Find Full Text PDFJCO Glob Oncol
January 2025
Auckland Regional Cancer and Blood Service, Te Toka Tumai Auckland, Health New Zealand, Te Whatu Ora, Auckland, New Zealand.
Purpose: In Aotearoa New Zealand, there are inequitable outcomes for Pacific peoples who experience higher rates of preventable cancers and poorer survival compared with other ethnicities. The aim of this study was to explore Pacific peoples lived experience of cancer and its treatment in the Auckland setting.
Methods: Data were collected through semistructured interviews (talanoa) with Pacific patients under the Auckland Regional Cancer and Blood Service.
JCO Glob Oncol
January 2025
Division of Medical Senology, European Institute of Oncology IRCCS, Milan, Italy.
Purpose: The use of social media is transforming physician-patient communication, mainly in the field of medical oncology. The pattern of social media use by medical oncologists is poorly studied. Therefore, we developed a survey to understand the preferences, experiences, opinions, and expectations of Italian medical oncologists and oncology fellows regarding the use of social media in cancer medicine to identify the different profiles of social media users.
View Article and Find Full Text PDFThe BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared with Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using the Lee Chronic GVHD Symptom Score and PROMIS subscales (physical function, GI symptoms, social role satisfaction) as primary end points and hemorrhagic cystitis symptoms and Lee subscales as secondary end points, responses from English and Spanish speakers were analyzed at baseline and days 100, 180, and 365 after transplant.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!